{
  "trial_id": "NCT00859339",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "Histological proof of muscle-invasive transitional cell carcinoma of the bladder",
      "label": "met"
    },
    {
      "criterion": "Age > 18 years at the time of consent",
      "label": "met"
    },
    {
      "criterion": "Written informed consent and HIPAA authorization for release of personal health information",
      "label": "met"
    }
  ],
  "exclusion": [
    {
      "criterion": "No prior radiotherapy to the pelvis",
      "label": "not_met"
    },
    {
      "criterion": "No prior malignancy is allowed except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, Gleason< grade 7 prostate cancers, or other cancer for which the patient has been disease-free for at least 5 years",
      "label": "unknown"
    },
    {
      "criterion": "No treatment with any investigational agent within 30 days prior to registration for protocol therapy",
      "label": "not_met"
    }
  ],
  "notes": "",
  "_meta": {
    "topic_id": "46",
    "trial_id": "NCT00859339",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}